In conclusion, our results suggest that A1AT can reverse the outer retinal alterations that occur during early AMD and can also ameliorate the severe wet AMD retinal phenotypes by inhibiting the pathological VEGF increase and CNV progression. Here, SERPINA1 is linked to wet macular degeneration.